Core Viewpoint - Sunshine Nuohuo (688621) announced the transfer of 70% equity in Shanghai Meisuke Data Co., Ltd. to Beijing Zhongjian Peilian Medical Research Institute for 2 million yuan, aiming to improve asset operation efficiency and reduce management costs due to Meisuke's long-term losses [1] Group 1 - Sunshine Nuohuo's wholly-owned subsidiary, Beijing Nuohuo Demai Pharmaceutical Technology Co., Ltd. (referred to as "Nuohuo Demai"), signed an equity transfer agreement with Zhongjian Peilian [1] - The decision to transfer the equity is based on the long-term loss status of Meisuke, with the goal of enhancing the company's sustainable operation capabilities [1] - The transaction also involves the transfer of part of the fundraising project related to the "Clinical Trial Service Platform Construction Project," of which Meisuke is one of the implementing entities [1]

分组1 - Weili Medical plans to distribute a cash dividend of 2 yuan per 10 shares to all shareholders, based on an undistributed profit of 704 million yuan as of September 30, 2025 [1] - Tongding Interconnect's shareholder plans to reduce their stake by up to 0.49%, equating to a maximum of 605,800 shares [1] - Caitong Securities has received approval from the China Securities Regulatory Commission to issue short-term corporate bonds with a total face value of up to 5 billion yuan [1] 分组2 - Youfu Food intends to use 70 million yuan of its own funds to invest in wealth management products with expected annual returns of up to 4.2% [3] - Keres received an administrative regulatory decision from the Guangdong Securities Regulatory Bureau for violations related to accounts receivable aging calculations and related party transactions [5] - Ouma Software's controlling shareholder has completed the transfer of state-owned equity, changing the controlling shareholder to Shandong Guotou [7] 分组3 - ST Huapeng's wholly-owned subsidiary has completed a major overhaul project and is now in production [8] - Beiqi Blue Valley has received approval from the China Securities Regulatory Commission for a stock issuance to specific investors [8] - Weijie Chuangxin received a government subsidy of 5 million yuan, accounting for 21.07% of its projected net profit for 2024 [9] 分组4 - China Resources Double Crane's subsidiary has received a drug registration certificate for a hypertension treatment drug [11] - Huafeng shares are continuing to suspend trading due to a planned change in control [13] - Kaifa Electric's shareholder plans to transfer 36.6869 million shares, representing 11.63% of the total share capital [14] 分组5 - Heng Rui Medicine has received approval for two clinical trials for innovative anti-tumor drugs [15] - Kosen Technology plans to invest 30 million USD to establish a new production base in Malaysia [17] - Sanxing Medical's subsidiary is expected to win a procurement project from the State Grid worth approximately 107 million yuan [18] 分组6 - Sitai Li's subsidiary has received a drug registration certificate for a contrast agent used in MRI [21] - Daren Tang's subsidiary has received a drug registration certificate for a pain relief gel [22] - Saike Xide has received approval for three medical device products, expanding its product range in the in vitro diagnostic field [23] 分组7 - Hasa Lian has elected a new chairman and vice chairman for its board of directors [24] - Two-sided Needle's subsidiary plans to invest 68.8522 million yuan in a production base expansion project [25] - Sunshine Nuohe plans to transfer 70% of its controlling subsidiary's equity for 2 million yuan [26] 分组8 - Hengbang shares received an administrative regulatory decision from the Shandong Securities Regulatory Bureau for failing to complete the election of independent directors [27] - Huali shares plan to sign a related transaction contract worth approximately 59.2847 million yuan [28] - Shangwei shares plan to invest 520.4 million yuan to gain a controlling stake in Sichuan Zhongfu Taihua [30] 分组9 - Zejing Pharmaceutical's ZG006 has been included in the list of breakthrough therapeutic varieties for treating advanced neuroendocrine cancer [32] - Yaopi Glass's shareholder plans to reduce their stake by up to 2.26%, equating to a maximum of 21.1469 million shares [34] - Huate Gas has initiated a major lawsuit involving a claim of 180 million yuan [36] 分组10 - Zhongchumei's controlling shareholder plans to increase their stake by between 42 million and 80 million yuan [37] - Huitong shares' shareholder plans to reduce their stake by up to 1% [38] - Miaowei Exhibition plans to apply for an initial public offering of H shares on the Hong Kong Stock Exchange [40] 分组11 - Tianqi Lithium's subsidiary has appealed to the Chilean Supreme Court regarding a partnership agreement with SQM and Codelco [42] - Naxin Micro plans to repurchase shares worth between 200 million and 400 million yuan [44] - Pingao shares have reported significant uncertainty regarding future business development and profitability [46] 分组12 - Shunyu shares have been pre-selected for a project worth 1.023 billion yuan [48] - Zhongyuan Neipei plans to acquire a 2.5% share in an aerospace industry fund for 50 million yuan [50] - Huifa Food's shareholder plans to reduce their stake by up to 3%, equating to a maximum of 727.14 million shares [53] 分组13 - Junshi Biosciences' subcutaneous PD-1 new formulation has reached its primary endpoint in a Phase III clinical trial [54] - Industrial Fulian clarified that it has not lowered its fourth-quarter profit target amid market rumors [55] - Longpan Technology's subsidiary has signed a major supply agreement for lithium iron phosphate materials, significantly increasing the supply volume [56]

Core Viewpoint - Sunshine Nuohuo announced the transfer of 70% equity in Shanghai Meisuke Data Co., Ltd. to Beijing Zhongjian Peilian Medical Research Institute for a cash consideration of 2 million yuan, while another 30% equity was transferred for 0 yuan, resulting in the exclusion of Meisuke Data from the company's consolidated financial statements [1][1][1] Group 1: Company Transactions - The transaction involves the transfer of equity stakes in Meisuke Data, which was part of a previously completed fundraising project related to the "Clinical Trial Service Platform Construction Project" [1][1] - After the transaction, Sunshine Nuohuo's subsidiary, Nuohuo Demai, will no longer hold any equity in Meisuke Data [1][1] Group 2: Financial Performance - For the first half of 2025, Sunshine Nuohuo's revenue composition indicates that 99.91% of its income is derived from CRO (Contract Research Organization) business, with only 0.09% from other business activities [1][1] - As of the report date, Sunshine Nuohuo's market capitalization stands at 7.1 billion yuan [1][1]

Market Overview - The medical services sector increased by 0.56% on November 25, with ST Zhongzhu leading the gains [1] - The Shanghai Composite Index closed at 3870.02, up 0.87%, while the Shenzhen Component Index closed at 12777.31, up 1.53% [1] Top Gainers in Medical Services - ST Zhongzhu (600568) closed at 2.57, up 4.90% with a trading volume of 53,900 shares and a turnover of 13.85 million yuan [1] - Chengda Pharmaceutical (301201) closed at 47.78, up 2.97% with a trading volume of 112,700 shares and a turnover of 540 million yuan [1] - Boji Pharmaceutical (300404) closed at 10.10, up 2.75% with a trading volume of 108,600 shares and a turnover of 10.9 million yuan [1] Top Losers in Medical Services - Jiuzhou Pharmaceutical (603456) closed at 18.75, down 0.85% with a trading volume of 181,100 shares and a turnover of 343 million yuan [2] - Tongce Medical (600763) closed at 41.95, down 0.66% with a trading volume of 49,600 shares and a turnover of 210 million yuan [2] - Yingkang Life (300143) closed at 10.12, down 0.49% with a trading volume of 44,700 shares and a turnover of 4.56 million yuan [2] Capital Flow Analysis - The medical services sector experienced a net outflow of 113 million yuan from institutional investors, while retail investors saw a net inflow of 30.37 million yuan [2][3] - Major stocks like WuXi AppTec (603259) had a net inflow of 67.13 million yuan from institutional investors, while Sunshine Nuohua (688621) saw a net outflow of 2.29 million yuan from retail investors [3] Summary of Individual Stock Performance - Sunshine Nuohua (688621) had a net inflow of 38.24 million yuan from institutional investors, but a net outflow of 3.59 million yuan from retail investors [3] - Chengda Pharmaceutical (301201) also saw a significant net inflow of 36.45 million yuan from institutional investors, with a net outflow of 13.58 million yuan from retail investors [3] - New Mileage (002219) had a net inflow of 14.15 million yuan from institutional investors, while retail investors experienced a net outflow of 6.70 million yuan [3]

鉴于美速科用长期处于亏损状态，综合考虑公司实际情况，为提升资产运营效率、降低管理成本、增强 持续经营能力，诺和德美拟对外转让美速科用70%股权。 格隆汇11月25日丨阳光诺和(688621.SH)公布，根据公司的整体经营规划，公司全资子公司诺和德美与 中健培联签署《上海美速科用数据有限公司股权转让协议》，诺和德美以200万元现金对价将其持有的 美速科用70%的股权转让给中健培联。交易完成后，诺和德美不再持有美速科用股权，美速科用不再纳 入公司合并报表范围。鉴于美速科用为已结项募投项目"临床试验服务平台建设项目"的实施主体之一， 故本次交易同时涉及部分募投项目转让。 ...

国联民生证券承销保荐有限公司 关于北京阳光诺和药物研究股份有限公司 转让控股孙公司股权暨募投项目转让的核查意见 国联民生证券承销保荐有限公司（以下简称"国联民生承销保荐"、"保荐机 构"）作为北京阳光诺和药物研究股份有限公司（以下简称"阳光诺和"、"公司"） 首次公开发行股票并在科创板上市的保荐机构，根据《证券发行上市保荐业务管 理办法》《上海证券交易所科创板股票上市规则》《上市公司监管指引第 2 号—— 上市公司募集资金管理和使用的监管要求》和《上海证券交易所科创板上市公司 自律监管指引第 1 号——规范运作》等相关规定，国联民生承销保荐对阳光诺和 转让控股孙公司股权暨募投项目转让情况进行了审慎核查，发表如下核查意见： 一、交易概述 （一）本次交易的基本情况 1、本次交易概况 根据公司的整体经营规划，公司全资子公司北京诺和德美医药技术有限公司 （以下简称"诺和德美"）与北京中健培联医学研究院（普通合伙）（以下简称"中 健培联"）签署《上海美速科用数据有限公司股权转让协议》，诺和德美以 200 万元现金对价将其持有的上海美速科用数据有限公司（以下简称"美速科用"） 70%的股权转让给中健培联。交易完成后，诺和 ...

证券代码：688621 证券简称：阳光诺和 公告编号：2025-104 北京阳光诺和药物研究股份有限公司 关于转让控股孙公司股权暨募投项目转让的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 根据公司的整体经营规划，北京阳光诺和药物研究股份有限公司（以下 简称"阳光诺和"或"公司"）全资子公司北京诺和德美医药技术有限公司（以下简 称"诺和德美"）与北京中健培联医学研究院（普通合伙）（以下简称"中健培联"） 签署《上海美速科用数据有限公司股权转让协议》，按照实缴出资比例，诺和德 美以 200 万元现金对价将其持有的上海美速科用数据有限公司（以下简称"美速 科用"）70%的股权转让给中健培联，上海诺和美创医药研究合伙企业（有限合 伙）（以下简称"诺和美创"）以 0 万元现金对价将其持有的美速科用 30%的股权 转让给中健培联。交易完成后，诺和德美不再持有美速科用股权，美速科用不再 纳入公司合并报表范围。 鉴于美速科用为已结项募投项目"临床试验服务平台建设项目"的实施主体 之一，故本次交易同时涉及部分募投项目转 ...

证券代码：688621 证券简称：阳光诺和 北京阳光诺和药物研究股份有限公司 2025 年第五次临时股东会会议资料 二〇二五年十一月 1 / 8 北京阳光诺和药物研究股份有限公司 2025 年第五次临时股东会会议资料 北京阳光诺和药物研究股份有限公司 2025 年第五次临时股东会会议资料 2025 年第五次临时股东会会议须知 为维护全体股东的合法利益，确保股东会的正常秩序和议事效率，保证会议 的顺利进行，北京阳光诺和药物研究股份有限公司（以下简称"公司"或"阳光诺 和"）根据《中华人民共和国公司法》（以下简称"《公司法》"）《中华人民共 和国证券法》（以下简称"《证券法》"）《北京阳光诺和药物研究股份有限公司 股东会议事规则》（以下简称"《股东会议事规则》"）以及《公司章程》的要求 及中国证监会、上海证券交易所的有关规定，特制定本须知。 一、为确认出席会议的股东或其代理人或其他出席者的出席资格，会议工作 人员将对出席会议人员的身份进行必要的核对工作，请被核对者给予配合。 出席会议的股东及股东代理人须在会议召开前 30 分钟到会议现场办理签到 手续，并请按规定出示身份证明文件或法人单位证明、授权委托书等，经验证 ...

证券代码：688621 证券简称：阳光诺和 公告编号：2025-106 北京阳光诺和药物研究股份有限公司 关于召开2025年第五次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东会类型和届次 2025年第五次临时股东会 召开日期时间：2025 年 12 月 12 日 14 点 30 分 召开地点：北京市昌平区科技园区双营西路 79 号院 29 号楼公司会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 12 月 12 日 至2025 年 12 月 12 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互联 股东会召开日期：2025年12月12日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 （二） 股东会召集人：董事会 （三） 投票 ...

证券代码：688621 证券简称：阳光诺和 公告编号：2025-105 表决情况：9票同意，0票反对，0票弃权。 本议案尚需提交公司股东会审议。 第二届董事会第二十七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 北京阳光诺和药物研究股份有限公司（以下简称"公司"或"上市公司"）于 2025年11月25日召开第二届董事会第二十七次会议。本次会议通知于2025年11 月21日以直接送达、传真与邮件方式发出，会议由董事长利虔先生召集和主持， 会议应出席董事9名，实际出席董事9名，会议的召集和召开符合《中华人民共和 国公司法》及《北京阳光诺和药物研究股份有限公司章程》等法律、行政法规、 部门规章、规范性文件的规定。 二、董事会会议审议情况 经与会董事认真审议，一致通过如下决议： （一）审议通过《关于转让控股孙公司股权暨募投项目转让的议案》 经审议，董事会同意公司全资子公司北京诺和德美医药技术有限公司（以下 简称"诺和德美"）与北京中健培联医学研究院（普通合伙）（以下简称"中健培联"） 签署 ...